Morgan Stanley is bullish on pelabresib, currently awaiting results from its Phase 3 MANIFEST-2 trial.
You are here: Home / This European biotech company could rally nearly 45%, says Morgan Stanley
Market News and Views
Morgan Stanley is bullish on pelabresib, currently awaiting results from its Phase 3 MANIFEST-2 trial.